PMC:7346000 / 29037-29265 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"775","span":{"begin":106,"end":114},"obj":"Species"},{"id":"782","span":{"begin":97,"end":105},"obj":"Disease"},{"id":"783","span":{"begin":218,"end":227},"obj":"Disease"}],"attributes":[{"id":"A775","pred":"tao:has_database_id","subj":"775","obj":"Tax:9606"},{"id":"A782","pred":"tao:has_database_id","subj":"782","obj":"MESH:C000657245"},{"id":"A783","pred":"tao:has_database_id","subj":"783","obj":"MESH:D003643"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"In other high-incidence settings, clinical antifungal prophylaxis trials will be conducted among COVID-19 patients admitted to the ICU aiming to show a decrease in putative [4] and proven IPA cases, as well as overall mortality."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T238","span":{"begin":97,"end":105},"obj":"Disease"}],"attributes":[{"id":"A238","pred":"mondo_id","subj":"T238","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"In other high-incidence settings, clinical antifungal prophylaxis trials will be conducted among COVID-19 patients admitted to the ICU aiming to show a decrease in putative [4] and proven IPA cases, as well as overall mortality."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T227","span":{"begin":150,"end":151},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"In other high-incidence settings, clinical antifungal prophylaxis trials will be conducted among COVID-19 patients admitted to the ICU aiming to show a decrease in putative [4] and proven IPA cases, as well as overall mortality."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T200","span":{"begin":43,"end":53},"obj":"Chemical"},{"id":"T201","span":{"begin":188,"end":191},"obj":"Chemical"}],"attributes":[{"id":"A200","pred":"chebi_id","subj":"T200","obj":"http://purl.obolibrary.org/obo/CHEBI_35718"},{"id":"A201","pred":"chebi_id","subj":"T201","obj":"http://purl.obolibrary.org/obo/CHEBI_17824"},{"id":"A202","pred":"chebi_id","subj":"T201","obj":"http://purl.obolibrary.org/obo/CHEBI_30802"}],"text":"In other high-incidence settings, clinical antifungal prophylaxis trials will be conducted among COVID-19 patients admitted to the ICU aiming to show a decrease in putative [4] and proven IPA cases, as well as overall mortality."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T60","span":{"begin":188,"end":191},"obj":"Phenotype"}],"attributes":[{"id":"A60","pred":"hp_id","subj":"T60","obj":"http://purl.obolibrary.org/obo/HP_0020103"}],"text":"In other high-incidence settings, clinical antifungal prophylaxis trials will be conducted among COVID-19 patients admitted to the ICU aiming to show a decrease in putative [4] and proven IPA cases, as well as overall mortality."}

{"project":"LitCovid-sentences","denotations":[{"id":"T160","span":{"begin":0,"end":228},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In other high-incidence settings, clinical antifungal prophylaxis trials will be conducted among COVID-19 patients admitted to the ICU aiming to show a decrease in putative [4] and proven IPA cases, as well as overall mortality."}

{"project":"2_test","denotations":[{"id":"32599813-30076119-60095168","span":{"begin":174,"end":175},"obj":"30076119"}],"text":"In other high-incidence settings, clinical antifungal prophylaxis trials will be conducted among COVID-19 patients admitted to the ICU aiming to show a decrease in putative [4] and proven IPA cases, as well as overall mortality."}